Abstract We present a case of an 81-year-old man with secondary autoimmune granulocytopenia in association with autoimmune thrombocytopenia. Treatment with granulocyte colony-stimulating factor (G-CSF) (5 mg/ kg/day s.c.) resulted in a rapid increase in the number of circulating granulocytes with a pronounced left shift. These changes were accompanied by up-regulation of the surface expression of FcgRI (CD64) and FcgRII (CD32) on the granulocytes. In addition, we noted a strong up-regulation of the FcgRIII (CD16) and the activation markers CD11b and CD66b on the granulocytes. The increase in the number of circulating granulocytes was followed by a dramatic decrease in the level of cell-bound as well as circulating anti-granulocyte antibodies. It is hypothezised that the decrease in the level of cell-bound as well as circulating anti-granulocyte antibodies may be the result of an increased adsorption of the antibodies by the granulocytes.
Introduction
Severe chronic neutropenia comprises a group of hematological disorders characterized by a decrease in circulating neutrophils, predisposing to recurrent infections, predominantly of the skin, mucosa, and upper respiratory tract [4] . Severe chronic neutropenia can be divided into congenital forms of neutropenia, cyclic neutropenia, and an ill-defined category of disorders including chronic idiopathic neutropenia and autoimmune neutropenia [4, 16, 21] . In primary autoimmune neutropenia (AIN) the neutropenia is the sole immunological abnormality, while in secondary AIN other immunological disorders are present [1, 16, 21] . In some of these patients AIN is associated with autoimmune hemolytic anemia, autoimmune thrombocytopenia, or a combination of both, with a roughly equal distribution among the three groups [16, 21] .
AIN is characterized by neutropenia with cell-bound and/or circulating anti-neutrophil antibodies directed against neutrophil-specific antigens [1, 20] . A number of anti-neutrophil antibody detection methods are available, the direct and indirect granulocyte immunofluorescence test (GIFT) being the most sensitive and the most widely used [1, 22, 23] . With this method immunoglobulin G (IgG) antibodies, mostly of the subclasses IgG 1 and IgG 3 , may be detected in patients with primary as well as with secondary AIN, sometimes together with IgM and IgA [1, 16, 21] . Several classes of neutrophil-specific antigens have been identified, which are present on mature myeloid cells, but also on myelocytes, promyelocytes, and even myeloblasts [1] . Autoantibodies have been detected against most of the neutrophil-specific antigens, particularly against NA 1 (up to 55%) [1] . In patients with secondary AIN it is often not possible to determine the specificity of the anti-neutrophil antibody [1] . Although neutropenia in AIN is primarily thought to be the result of peripheral destruction of antibody-coated neutrophils, the neutrophil-specific autoantibodies may also interfere with myelopoiesis, leading to a maturation arrest that may occur at various stages of the myelopoiesis, likely to be dependent on the type of antigen against which the antibody is directed [1, 20] .
Treatment of AIN consists primarily of the administration of appropriate antibiotics when infection is present. The efficacy of immunomodulation such as the administration of corticosteroids, high-dose gammaglobulin, or splenectomy in primary and secondary AIN is unpredictable [1, 2, 3, 19] . Unexpectedly, recent case reports have revealed a therapeutic role for the hematopoietic growth factors in patients with AIN [8, 13, [18] [19] [20] . Both granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) have been successfully applied in patients with AIN associated with the Felty's syndrome [2, 10] , systemic lupus erythematosus [6] , and a variety of other conditions [8, 13, [18] [19] [20] . In one report of a child with chronic AIN, treatment with G-CSF, instituted 2 weeks after the start of prednisone, led to an increase of the circulating granulocytes with the disappearance of the anti-granulocyte antibodies [14] .
In this report we describe the results of G-CSF administration in an adult patient with secondary granulocytopenia. We examined its effect on the level of the circulating and cell-bound anti-granulocyte antibodies. We observed that G-CSF treatment resulted in a rapid increase in the number of circulating granulocytes, followed by a significant decrease in the anti-granulocyte autoantibody levels. Furthermore, we studied the effects of G-CSF on the Fcg receptor profile of the granulocytes.
Case report
A 81-year-old Caucasian man was admitted because of fever and perianal discomfort, several weeks after undergoing fine-needle biopsy of the prostate. Previously he had had no serious or recurrent infections. Initial physical examination revealed no gross abnormalities; there was no splenomegaly. Laboratory examination showed an ESR of 92 mm (normal ~10 mm), the leukocyte count was 1.8!10 9 /l (normal 4-10!10 9 /l) with 1% blasts, 2% eosinophils, 1% bands, 6% segmented neutrophils, 53% lymphocytes, and 37% monocytes. Hemoglobin was 4.9 mmol/l (normal 8.4-11.2 mmol/l), reticulocytes 2.1% (normal 1-2%), and the platelet count was 281!10 9 /l (normal 150-350!10 9 /l). The biochemistry profile was normal, without signs of hemolyis (haptoglobin 0.6 g/l (normal 0.3-1.8), lactate dehydrogenase 154 units/l (normal 290)). Red cell transfusion was complicated by chills and highgrade fever. Bone marrow examination revealed a hypercellular marrow, active and left-shifted myelopoiesis with normal myeloid maturation, diminished erythropoiesis -myeloid/erythroid (M/E) ratio of 7.5 -, and normal megakaryopoiesis. During the subsequent days fever and granulocytopenia (~0.3!10 9 /l) persisted and a perianal infiltrate became apparent. The patient was treated with amoxycillin clavulanate, gentamicin, and G-CSF (filgastrim, Neupogen) (3 mg/kg s.c.), and the fever subsided. After three daily subcutaneous injections of G-CSF the granulocyte count had increased to 0.5!10 9 /l, reaching a maximum of 26.1!10 9 /l after a total of 13 administrations. The perianal infiltrate healed. The direct IgG antiglobulin (Coombs) test and direct IgG platelet immunofluorenscence test (PIFT) were positive, but the direct and indirect granulocyte immunofluorescence tests (GIFT) were negative. Tests for rheumatoid factor, antinuclear and anti-dsDNA antibodies, and circulating immune complexes (C1 q -binding) were negative. Serum immunoglobulin levels were within the normal range. Following discontinuation of G-CSF the granulocyte count gradually returned to baseline levels.
During the subsequent 3 months the granulocytopenia persisted (~0.5!10 9 /l) without signs of infection. Then suddenly, the platelet count decreased from 156 to 11!10 9 /l. Hemoglobin was 7.2 mmol/l, and there were no signs of hemolysis. The direct GIFT and the direct Coombs test were negative. Bone marrow examination revealed active megakaryopoiesis and myelopoiesis. Adminstration of prednisone (1 mg/kg/day) resulted in a gradual increase of the granulocyte count (0.35!10 9 /l before treatment, 0.91!10 9 /l at day 2, 1.6!10 9 /l at day 6, with a maximum of 12.5!10 9 /l at day 11 of treatment) and in normalization of the platelet count within 20 days. The hemoglobin level normalized. The dose of prednisone was slowly tapered and was discontinued after 21 weeks. During the treatment period the platelet count remained within the normal range. The granulocyte count gradually decreased to approximately 1.5!10 9 /l as the prednisone dose was tapered. Approximately 50 days after discontinuation of the prednisone the granulocyte count had decreased tõ 0.5!10 9 /l, and the platelet count gradually declined to 70!10 9 /l. At that time the direct and indirect GIFT and PIFT showed the presence of IgG autoantibodies, and the direct Coombs test was negative. It was decided to retreat the patient with G-CSF (5 mg/ kg s.c.) and to examine the hematological effects, the kinetics of the Fcg-receptor expression on the neutrophils, and the levels of the anti-granulocyte and anti-platelet antibodies.
Materials and methods
The scheme of G-CSF administration was adjusted in order to keep the granulocyte count above 1!10 9 /l and to avoid granulocyte counts above 30!10 9 /l. Venous blood samples (EDTA anticoagulated, serum and plasma) were obtained 4 days and just prior to the first injection of G-CSF and at days 1, 2, 4, 7, 9, 14, 21, and 28 for the direct antiglobulin test, the direct and indirect GIFT, the direct and indirect PIFT, the direct and indirect monoclonal antibody-specific immobilization of platelet antigens (MAIPA) tests, and the determination of the total IgG and antitoxoplasma IgG levels. Immunophenotyping was done with leukocytes isolated from EDTA-anticoagulated venous blood samples obtained at days P4, 0, 1, 2, 4, 7, 9, and 14. During the treatment period hemoglobin level, leukocyte count with differential, platelet, and reticulocyte counts were measured daily and an extensive biochemistry profile including haptoglobin was determined on a regular basis. Bone marrow examination was done just prior to and 4 days after the start of G-CSF treatment. Mean values of four bone marrow differentials of 500 nucleated cells, counted by an independent investigator (Mrs. E. Wijn-Maas) were calculated. The differential of myeloid bone marrow cells was expressed as percentage of the total myeloid cells.
Immunophenotyping
The leukocytes were isolated for flow-cytometric analysis as previously described [11] . The neutrophils were gated based on forward and side-scatter parameters and the phenotype of the neutrophils was determined by indirect one-color immunofluorescence. The murine monoclonal antibodies (MoAb) used were CD11b (C3bi receptor, CLB-B2.12, Central Laboratory of the Red Cross Blood Transfusion Service, Amsterdam, the Netherlands), CD14 (CLB mon/l, CLB), CD66b (B 13.9, CLB), CD34 (HPCA-1, Becton-Dickinson, San Jose, Calif.), CD64 (FcgRI, 22, Medarex, West Lebanon, NH), CD32 (FcgRII, IV.3, Medarex) and CD16 (FcgRIII, 3G8 Medarex and CLB FcRgran 1, CLB). The data are expressed as the mean fluorescence intensity.
Detection of autoantibodies against granulocytes and platelets
The direct and indirect granulocyte immunofluorescence tests were performed as previously described [22, 23] . For quantitation of the indirect GIFT, serum of the patient was tested after twofold serial dilution, and mean fluorescence intensity was documented. The indirect GIFT was performed by testing neutrophils from a single donor, and all samples were analyzed in the same experiment. In order to detect the specificity of the circulating antibody, donor granulocytes with known NA, NB, and 5b phenotype were used.
In the direct and indirect platelet immunofluorescence tests (PIFT) the reactions were scored using fluorescence microscopy [24] . The specificity of the platelet-associated autoantibodies and alloantibodies, respectively, was tested in the direct and indirect monoclonal antibody-specific immobilization of platelet antigens (MAIPA) originally described by Kiefel et al. [12] . A panel of murine monoclonal antibodies against various glycoproteins (GP) or glycoprotein complexes were incubated with donor platelets and patient's serum (indirect MAIPA) or patient's platelets (direct MAIPA). The MoAbs used were CD41 (GP IIb/IIIa, CLBtromb/7, CLB), CD42a (GP Iba, CLB-MB45), CD36 (GP IV, P58, CLB), CD42d (GP V, CLB-SW16, CLB) and CD49b (GP Ia, CLB-tromb-4, CLB).
Results

Hematological effects of G-CSF
G-CSF was administered from days 0 to 4 and on days 6, 7, 11, 32, and 49. During the first days of treatment we observed a dramatic and rapid increase in the number of circulating leukocytes and granulocytes. On days 0, 1, 2, 3, and 4 the granulocyte count was 0.35, 5.7, 8.8, 12.4, and 15.3!10 9 /l, respectively. On day 8 we noted a more than tenfold increase in the number of circulating leukocytes, and a nearly 100-fold increase in the number of granulocytes. On day 4, 17% of the leukocytes were band forms. No significant number of metamyelocytes or myelocytes appeared in the blood. At day 4 of treatment the number of circulating lymphocytes had gradually increased from 1.8 to 5!10 9 /l and the number of circulating monocytes had gradually increased from 0.4 to 1.6!10 9 /l. No changes in the eosinophil count occurred. No significant changes in the hemoglobin level, reticulocyte count, or the biochemical profile were noted. Also, no unequivocal effect on the course of the platelet count was detected.
Bone marrow examination before treatment revealed active myelopoiesis with 4% myeloblasts, 6% promyelocytes, 12% myelocytes, 40% metamyelocytes, 33% bands, and 5% segmented forms, the M/E ratio was 3.6. At day 4 of treatment with G-CSF the myelopoiesis was increased, with 3% myeloblasts, 37% promyelocytes, 16% myelocytes, 19% metamyelocytes, 14% bands, and 11% segmented forms, indicating an augmented proliferation of myeloid progenitor cells and an increased maturation. The M/E ratio was 10.1.
During the follow-up period of more than 1 year after the last G-CSF administration the granulocyte count varied between 0.3 and 1.2!10 9 /l without infectious complications.
Immunophenotyping of the granulocytes during in vivo administration of G-CSF As expected, before treatment with G-CSF the circulating granulocytes showed no expression of FcgRI (CD64) and a normal low expression of FcgRII (CD32) Fig. 1a-c The effects of G-CSF (5 mg/kg s.c.) on the number of circulating granulocytes and the surface expression of FcgRI (CD64) (a), FcgRII (CD32) (b), and FcgRIII (CD16) (c) on the granulocytes measured by flow cytometry on days P4, 0, 1, 2, 4, 7, and 14 of G-CSF treatment [11] . Upon adminstration of G-CSF the expression of FcgRI and FcgRII significantly increased, coinciding with the increase of the granulocyte count. After discontinuation of the G-CSF the expression of FcgRI and FcgRII decreased only gradually despite the rapid decline of the granulocyte count (Fig. 1a, b) . During the Fig. 2a, b The effects of G-CSF (5 mg/kg s.c.) on number of circulating granulocytes and surface expression of activation markers CD11b (a) and CD67 (b) on granulocytes measured by flow cytometry on days P4, 0, 1, 2, 4, 7, and 14 of G-CSF treatment first days of G-CSF treatment the expression of FcgRIII (CD16) on the circulating granulocytes decreased slightly, but upon further G-CSF administration the expression of FcgRIII strongly increased, concurrent with the increase of the granulocyte count, and remained high despite the decrease of the granulocyte count following discontinuation of G-CSF (Fig. 1c) . Expression of the activation markers CD11b and CD66b strongly increased during treatment with G-CSF and was further augmented despite discontinuation of G-CSF (Fig. 2a, b) . The expression of CD14 was closely correlated with the granulocyte count (data not shown). Within the total leukocyte count there was a 10-to 20-fold increase in the number of circulating CD34 c cells, although the percentage of CD34 c cells (B0.2%) did not change significantly.
Autoantibodies levels
Before treatment with G-CSF, circulating and cellbound IgG anti-granulocyte antibodies were easily de- Table 1 The mean fluorescence intensity of the indirect and direct GIFT before and during treatment with G-CSF (5 mg/kg s.c.)
Day
Indirect GIFT Direct 0  1  2  4  7  9  14  21  28   750  931  965  805  673  487  487  422  453  379   470  470  542  487  470  264  255  246  198  237   305  294  274  274  284  165  165  149  111  213   165  160  165  154  129  100  100  93  84  87   198  205  274  305  487  254  264  205  178  205 a The indirect GIFT was tested with patient's serum after a twofold dilution series tected by the indirect and direct GIFT. Unfortunately, no specificity of the antibody was determined; specificity for the NA, NB, and 5b system was excluded. During the first days of treatment no significant change in the level of circulating anti-granulocyte antibodies was noted, but at day 7 of treatment a significant decrease in the indirect GIFT level had occurred that persisted throughout the observation period of up to 28 days after the start of G-CSF administration (Table 1) , at which time point the granulocyte count had returned almost to pretreatment levels. In Fig. 3a the courses of the circulating granulocytes and the anti-granulocyte antibody levels are depicted, showing that the increase in the number of circulating granulocytes preceded the decrease in the anti-granulocyte antibody level.
The level of the cell-bound anti-granulocyte antibodies (direct GIFT) significantly increased during the first 4 days of G-CSF treatment. This increase may reflect an increased binding of the antibodies, possibly due to a G-CSF-mediated up-regulation of antigen expression. Between the 4th and 7th day there was a dramatic decrease in the direct GIFT level, which returned to pretreatment values. As indicated in Table 1 and Fig.  3b , the decrease of the level of circulating anti-granulocyte antibodies tended to coincide with the decrease of the cell-bound antibodies.
No changes occurred in the serum IgG level and the anti-toxoplasma IgG level. These data indicate an absolute and selective G-CSF-associated decrease in the level of circulating as well as cell-bound anti-granulocyte antibodies. During the subsequent 6 months the level of circulating anti-granulocyte antibodies did not change significantly.
Platelet-specific autoantibodies were detected in the direct PIFT; they were specified by using the direct MAIPA as antibodies directed against glycoprotein V (CD42d) and glycoprotein IV (CD36). The indirect PIFT only showed very weak reactions that were not confirmed in the indirect MAIPA. The level of the platelet-specific autoantibodies did not change during G-CSF treatment.
Discussion
In this report we describe the effects of G-CSF administration in a patient with secondary autoimmune granulocytopenia. The administration of G-CSF resulted in a rapid increase in the number of circulating granulocytes. This restoration of the granulocyte count was associated with a significant decrease in the level of cellbound and circulating anti-granulocyte antibodies. The amount of increase and kinetics of the granulocytes during the administration of G-CSF in this patient are comparable to those observed in healthy volunteers [15] .
As expected, we observed significant changes in the surface expression of the Fcg receptors on the circulating granulocytes during and after G-CSF administration. Three classes of Fcg receptors capable of binding the Fc region of IgG have been identified on human blood cells [7, 9] . No expression of FcgRI (CD64) was found on the granulocytes, but during G-CSF administration a rapid increase of FcgRI expression was noted. After the first injections of G-CSF no changes in the expression of FcgRII (CD32) occurred on the granulocytes, but after repeated administration of G-CSF the expression of FcgRII was strongly increased. The level of FcgRI and FcgRII expression gradually decreased after discontinuation of G-CSF. The events are in line with those observed in healthy G-CSF-treated volunteers [5, 11, 17] . Normal granulocytes also express FcgRIII (CD16) on their surface. Other than in healthy volunteers [17] , during treatment with repeated G-CSF injections we noted a significant and gradual increase in the FcgRIII expression that persisted for at least 3 days after discontinuation of G-CSF. The activation markers CD11b and CD66b followed the same pattern. These data are difficult to interpret, but they may imply that normal granulocytes reacted differently from the patient's granulocytes upon G-CSF administration.
The course of the cell-bound and circulating antigranulocyte autoantibody levels is most intriguing. During the first days of G-CSF treatment the cellular binding of the anti-granulocyte antibodies significantly increased, probably as the result of G-CSF-mediated up-regulation of the antigen. Since the granulocyte count strongly increased, these events had apparently no effect on the removal of the cells from the circulation.
Between the 4th and 7th day of G-CSF treatment a dramatic decrease in the level of cell-bound and circulating anti-granulocyte antibodies occurred. In view of the unchanged serum levels of IgG and anti-toxoplasma IgG, it is unlikely that the decrease was due to aspecific binding effects.
We propose that the decrease in the circulating antigranulocyte antibodies is due to adsorption of the antibody by the granulocyte. Binding of the antibody to the granulocyte, increased during the first days of G-CSF treatment, may result in adsorption of the antibody due to internalization of the antigen-antibody complex and, subsequently, in clearance of the antibody. The courses of the levels of the circulating and cell-bound anti-granulocyte antibodies are consistent with this adsorption mechanism.
In summary, this report confirms isolated case reports that administration of G-CSF may be of benefit to patients with autoimmune granulocytopenia [2, 6, 13, 14, 19, 20] . With respect to the G-CSF-related increase of the circulating granulocytes, two mechanisms seem to be involved in this patient. First, during the first days the increase may be the result of G-CSF-induced proliferation and mobilization of neutrophils from the bone marrow. Second, within 1 week of treatment there was a decrease in the level of cell-bound and circulating anti-granulocyte antibodies, most likely due to a G-CSF-induced increase in adsorption of the antibody.
